Ho Kyung Seo

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni et al. · The Lancet Oncology · 2021 · 513 citations

Urology, Surgical Oncology, Genitourinary Cancer +7

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

Arjun Vasant Balar, Girish S. Kulkarni, Edward Uchio et al. · Journal of Clinical Oncology · 2019 · 113 citations

Urology, Phase Ii Trial, Genitourinary Cancer +13

Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer

Kang Su Cho, Ho Kyung Seo, Jae Young Joung et al. · The Journal of Urology · 2009 · 106 citations

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

Andrea Necchi, M. Roumiguié, Ashish M. Kamat et al. · The Lancet Oncology · 2024 · 73 citations · Full text

Urology, Surgical Oncology, Oncology +6

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 69 citations · Full text

Metastatic Urothelial Cancer, Urology, Genitourinary Cancer +7